10x Genomics (TXG) Misses Q4 EPS by 9c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
10X Genomics (TXG) PT Lowered to $20 at Citi
February 13, 2025 6:40 AM ESTCiti analyst Patrick Donnelly lowered the price target on 10X Genomics (NASDAQ: TXG) to $20.00 (from $23.00) while maintaining a Buy rating.
The analyst comments "After pre-announcing last month, TXG reported official 4Q revenue of $165mn, above FactSet consensus of ~$160mn and the... More
